Wall Street brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to post earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for AVEO Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). AVEO Pharmaceuticals posted earnings of ($0.08) per share in the same quarter last year, which would suggest a positive year over year growth rate of 25%. The company is expected to report its next earnings report on Wednesday, August 8th.
On average, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.31) to ($0.23). For the next financial year, analysts forecast that the business will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.62) to ($0.16). Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover AVEO Pharmaceuticals.
Get AVEO Pharmaceuticals alerts:
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.98 million.
A number of brokerages have recently commented on AVEO. ValuEngine raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, May 4th. Finally, BidaskClub downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.05.
NASDAQ:AVEO traded up $0.01 during trading hours on Friday, hitting $2.21. The company’s stock had a trading volume of 2,270,470 shares, compared to its average volume of 1,149,993. The firm has a market capitalization of $262.70 million, a PE ratio of -13.81 and a beta of 1.52. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of -0.36. AVEO Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $4.24.
In related news, major shareholder Ravi Viswanathan bought 70,873 shares of the business’s stock in a transaction that occurred on Tuesday, May 8th. The shares were bought at an average price of $2.13 per share, with a total value of $150,959.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Equity Opportunities Iv Growth bought 236,479 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The shares were bought at an average cost of $2.13 per share, for a total transaction of $503,700.27. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 2,098,458 shares of company stock worth $4,701,711. 4.40% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. Prosight Management LP purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $2,951,000. Point72 Asset Management L.P. boosted its position in shares of AVEO Pharmaceuticals by 213.5% during the first quarter. Point72 Asset Management L.P. now owns 940,403 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 640,403 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of AVEO Pharmaceuticals by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 667,956 shares of the biopharmaceutical company’s stock valued at $1,863,000 after buying an additional 40,616 shares during the last quarter. Emory University purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,682,000. Finally, Armistice Capital LLC purchased a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,674,000. 50.31% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com